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Abstract
Objective: Depressed patients rate social support as important for prognosis, but 
evidence for a prognostic effect is lacking. We aimed to test the association between 
social support and prognosis independent of treatment type, and the severity of de-
pression, and other clinical features indicating a more severe illness.
Methods: Individual patient data were collated from all six eligible RCTs (n = 2858) 
of adults seeking treatment for depression in primary care. Participants were rand-
omized to any treatment and completed the same baseline assessment of social support 
and clinical severity factors. Two- stage random effects meta- analyses were conducted.
Results: Social support was associated with prognosis independent of randomized 
treatment but effects were smaller when adjusting for depressive symptoms and dura-
tions of depression and anxiety, history of antidepressant treatment, and comorbid 
panic disorder: percentage decrease in depressive symptoms at 3– 4 months per z- score 
increase in social support = −4.14(95%CI: −6.91 to −1.29). Those with a severe lack 
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1 |  INTRODUCTION
The majority of adults treated for depression will not remit 
with the first treatment they receive.1,2 There is a lack of evi-
dence to guide clinicians on what information can be gath-
ered pre- treatment to better inform prognosis for depressed 
patients.3,4 Such knowledge can aid the future clinical man-
agement of the patient's condition, and many clinicians and 
patients want to know what the patient's prognosis is.5
Studies asking patients about the things they consider to 
be particularly important to their short- term and longer- term 
prognoses have highlighted social support as a key factor.6 
There is no universally accepted definition of social support 
so for the purposes of this article we propose a working defi-
nition as an individual's perception that they are cared for, 
esteemed, loved, or valued by their peers, friends, or family, 
and are part of a social network that can be mobilized when 
needed.7,8 Social support is somewhat related to other social 
factors such as loneliness and social isolation, although they 
are considered distinct from one and other.9 Loneliness is 
sometimes defined as the gap between desired social con-
tacts (both the amount of them and perceived quality of 
them) and the social contacts one experiences.10 In con-
trast, social isolation is often defined as the objective rather 
than subjective rating of the quantity and mobilization of 
one's social network.10 Social support has been found to be 
an important modifiable target for preventive interventions 
11 and has been raised as a priority area by clinicians and 
health policy makers over recent years.9,12- 14 The associa-
tion between social support and the onset of depression is 
well established,11,15,16 and hence in this study, we focus on 
social support alone, without also studying social isolation 
or loneliness. There are a number of proposed mechanisms 
by which better social support might help mitigate against 
depression, for example perceiving oneself as belonging to 
a supportive network has been associated with a number of 
positive health outcomes.7 In addition, social support can act 
as a buffer against stress,17 whether that be because mem-
bers of a social network help solve stress- related problems, 
stop one from directly facing the impact of stressful situa-
tions, or by mitigating the impact of stress, this buffering 
against stress might reduce the probability of depression 
occurring.7 Unlike other known prognostic factors for de-
pression, social support might be modifiable,11 and as such, 
knowing whether it is associated with prognosis could be of 
clinical value.
Despite evidence for an association with the onset of 
depression, the association between social support and 
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of social support had considerably worse prognoses than those with no lack of social 
support: increase in depressive symptoms at 3– 4 months = 14.64%(4.25% to 26.06%).
Conclusions: Overall, large differences in social support pre- treatment were associ-
ated with differences in prognostic outcomes. Adding the Social Support scale to clin-
ical assessments may be informative, but after adjusting for routinely assessed clinical 
prognostic factors the differences in prognosis are unlikely to be of a clinically impor-
tant magnitude. Future studies might investigate more intensive treatments and more 
regular clinical reviews to mitigate risks of poor prognosis for those reporting a severe 
lack of social support.
K E Y W O R D S
depression, social support, prognosis, treatment outcome, individual patient data meta- analysis
Summations
• Social support was associated with prognosis in-
dependent of randomized treatment
• A severe lack of social support was associated 
with considerably worse prognosis
• Social support should be routinely assessed when 
adults present with depression
Limitations
• We adjusted for routinely assessed clinical prog-
nostic factors as this tells us about the import of 
assessing social support in clinic
• But this might have greatly reduced the apparent 
size of the associations.
• Studying the causal pathways between social 
support and prognosis for adults with depression 
would be very informative but this study was un-
able to address that question
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prognosis is not well evidenced.18 Findings from our recent 
meta- review 4 suggest that only four previous systematic re-
views have reported on the associations between social sup-
port and prognosis for adults with depression.10,16,19,20 Those 
reviews found some limited evidence that low social support 
is associated with poorer prognosis; however, they contained 
very few primary studies investigating the effect. There were 
also a number of methodological problems with the reviews 
including the combination of different prognostic outcomes 
(such as treatment response and relapse),19 combinations of 
outcomes at very different post- baseline end points (from 
two weeks to two years),19 and a combination of different 
ways of measuring and quantifying social support,10,16,20 
making it difficult to interpret sources of heterogeneity. 
There was also a lack of clarity on the setting and context of 
recruitment of participants,10,20 and combinations of some 
treated samples with mainly community- based, non- treated 
samples,10 making it difficult to determine the generalizabil-
ity of the findings. Most of the primary studies reviewed 
by the past reviews were cohort studies in which there were 
typically few people with depression, and most had not 
sought treatment. As such, inferences about the association 
between social support and prognosis have been imprecise 
and might not generalize to the population of treatment- 
seeking patients seen in clinical practice. Further, none of 
the reviews investigated the association between social sup-
port and prognosis regardless of the type of treatment re-
ceived (we call this prognosis “independent of treatment”), 
so the question remains as to whether or not social support 
is only associated with particular types of treatment, for ex-
ample, antidepressants as studied in one previous review,20 
or is associated with prognosis in general. To answer such a 
question, data are required from participants that received a 
range of commonly available treatments, delivered to a set 
standard, so the effects of treatment can be controlled for in 
a model of prognosis. This ensures that results are generaliz-
able, at least to patients that may receive one of those treat-
ments. In addition, the prior reviews did not investigate the 
potential for individual items of a measure of social support 
to capture the association between social support and prog-
nosis. Such findings might have important utility in clinical 
settings in which completing a full scale measuring social 
support may not be possible given time pressures. It is also 
noteworthy that past studies and reviews have either rarely 
included data from primary care settings, or have not given 
sufficient information about the settings participants were 
recruited from to know whether the results are generalizable 
to other health service settings. In the UK, as elsewhere, the 
majority of adults with depression initially seek help from 
primary care settings.21- 23 Identifying prognostic factors in 
a primary care sample, independent of treatments, would 
therefore have important utility.
In a recent study, we found that depressive symptom se-
verity was the strongest indicator of prognosis independent 
of treatment and we found that a number of other clinical fea-
tures of depressive illness (depressive “disorder character-
istics”) including the durations of depression and comorbid 
anxiety, comorbid panic disorder and a history of antide-
pressant treatment, were also independently associated with 
prognosis.4 No prior studies have investigated associations 
between social support and prognosis independent of these 
clinical markers of severity, so we do not know whether as-
sessing for social support might prove informative for the 
clinical management of depression over and above these fac-
tors that should be, and often are, routinely assessed in clinic.
1.1 | Aims of the study
This study aimed to 1) investigate whether social support is 
associated with prognosis for adults with depression inde-
pendent of treatment, and independent of depressive “disor-
der characteristics”; and 2) to investigate whether individual 
items of a scale measuring social support are associated with 
prognosis independent of treatment and depressive “disorder 
characteristics”.
2 |  METHODS AND MATERIALS
2.1 | Identification and selection of studies
The protocol for identifying studies and a description of the 
formation of the Depression in General Practice (Dep- GP) 
individual patient data (IPD) dataset was pre- registered 
(PROSPERO: CRD42019129512 (01/04/2019)), details in-
cluding the process of developing and amending the protocol 
have been described elsewhere,3 and further details are also 
given in the Supplementary Materials.
We conducted scoping searches to identify the most com-
monly used diagnostic screening tool and symptom measure 
used in randomized controlled trials (RCTs) recruiting adults 
with depression in primary care, that included depressive 
symptoms and a wide range of anxiety disorders and symp-
toms. This was in order to ensure that studies included here 
would have data on the range of clinical prognostic factors or 
depressive “disorder characteristics” that might be routinely 
assessed in clinic, so that we could ascertain whether or not 
social support is informative of prognosis in addition to those 
clinical factors. From those searches, we identified that this 
was the Revised Clinical Interview Schedule (CIS- R).24 The 
use of this measure at baseline was therefore made an inclu-
sion criterion for our searches. Keeping this consistent mini-
mizes bias in harmonizing data across studies.
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T A B L E  1  Measures used across the studies of the Dep- GP IPD database
Measure Details Scores and cutoffs for remission
CIS- R24 Consists of 14 symptom subsections scored 0– 4 
covering core features of depression, depressive 
thoughts (scored 0– 5), fatigue, concentration/
forgetfulness, and sleep, generalized anxiety, 
worry, irritability, obsessions, compulsions, 
health anxiety, somatic concerns, phobic anxiety 
(split into agoraphobia, social phobia, and specific 
phobia), and panic. A final section measures 
general health, impairment, and weight change.
The total score ranges from 0 to 57 with 
a cutoff of ≥12 used to indicate likely 
common mental disorder, primary and 
secondary diagnoses using ICD−10 
criteria are given as are binary indictors 
of diagnosis for all the disorders 
assessed. Scores of <12 among those 
that were previously depressed can be 
used to indicate remission.
Beck Depression Inventory 2nd Edition 
(BDI- II) 43
Consists of 21 items to assess depressive symptoms, 
each item is scored 0– 3.
There is a maximum score obtainable of 
63, and a cutoff of ≥10 is used indicate 
significant symptoms of depression, 
scores of <10 are therefore used to 
indicate remission in those that were 
previously depressed/scored ≥10.
Patient Health Questionnaire 9- item 
version (PHQ−9) 44
This is a depression screening measure, with 
respondents asked to rate how often they have 
been bothered by each of the nine symptom 
items over the preceding two weeks. Each item is 
scored 0– 3
There is a maximum score of 27 with 
a cutoff of ≥10 is used to indicate 
“caseness” for depression, a score of 9 
or below for those that were previously 
depressed is therefore considered to 
indicate remission
Social Support Scale— adapted by 
authors of RCTs included in this 
IPD by adding one item to the 
Health and Lifestyle Survey Social 
Support Measure.25
An 8- item instrument (the first seven of which are 
from the Health and Lifestyle Survey) assessing 
the degree to which participants rated the social 
support of their friends and family in each of 
the following domains: 1) being accepted for 
who one is; 2) feeling cared about; 3) feeling 
loved; 4) feeling important to them; 5) being 
able to rely on them; 6) feeling well supported 
and encouraged by them; 7) being made to feel 
happy by them; and 8) feeling able to talk to them 
whenever one might like. Items are scored 1– 3, 
with total scores ranging from 8 to 24; higher 
scores indicate higher levels of perceived social 
support. The authors of the Health and Lifestyle 
Survey suggested the maximum score for social 
support (which was 21 on that scale) indicated 
“no lack of social support” scores between 18 and 
20 indicated a “moderate lack of social support” 
and scores of 17 or below indicated a “severe lack 
of social support”.
N/A
Life events: adapted by the authors of 
the Adult Psychiatric Morbidity 
Surveys 21 based on the Social 
Readjustment Rating Scale 45
Participants are asked to say yes/no to whether they 
have suffered any of nine events within the last 
six months, for example, a death/bereavement; 
being physically attacked/injured; or going 
through a divorce/separation. Each item is scored 
yes 1 or no (0), and the total score is the sum of all 
the items.
N/A
Alcohol use: the alcohol use disorder 
identification test primary care 
version (AUDIT- PC).46
Used to assess alcohol misuse, this includes five 
items scored 0– 4. A cutoff of ≥5 indicates 
hazardous alcohol use that may be harmful to 
one's health
N/A
Note: All measures apart from the PHQ- 9 were used in all six studies; PHQ- 9 was used in three studies (COBALT, MIR, and PANDA).
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In brief, in the final searches studies were identified via 
searches on bibliographic databases (Medline, Embase, 
PsycINFO, and Cochrane Central, searched from inception 
to December 1, 2020), hand- searching of reference lists, 
and contacting experts for unpublished or missed studies. 
Search terms included variations of phrases such as “de-
pression” or “major depression”, “RCT” or “Randomized 
Controlled Trial”, and “CIS- R” or “Clinical Interview 
Schedule”. See Table S1 for a full list and results of the 
searches.
A single reviewer (JB) screened titles and abstracts of 
potentially eligible studies, these were then read in full and 
judged against inclusion/exclusion criteria by two reviewers 
(JB and GL) with consultation with a third (SP) to resolve 
any uncertainties by consensus.
2.1.1 | Inclusion and exclusion criteria
Studies were included in the IPD if they were RCTs of adults 
seeking treatment for depression from a general practitioner/
family physician, with unipolar depression confirmed via 
the revised clinical interview schedule (CIS- R)24 at baseline. 
Studies in the present analyses also had to use the Social 
Support Scale from the Health and Lifestyle Survey 25 at 
baseline.
Details of the measures used in the included studies from 
Dep- GP that are relevant to the analyses described here are 
in Table 1.
2.1.2 | Data extraction
The included studies are detailed in Table 2. Data were 
extracted for each study participant on all variables in 
Table  3 by the chief investigators or data managers of 
each individual study. Data were cleaned one study at a 
time, independently by two reviewers (JB and RS), and 
cross- checked with publications and via liaison with 
chief investigators for each study. Issues were resolved 
by  consensus between four reviewers (JB, RS, GL, and 
SP).
2.1.3 | Data integrity checks
Integrity of all baseline and endpoint data for each study was 
checked with the study team and against publications from 
each study. The numbers of participants included here are 
very slightly different than those in the published articles 
about the individual studies as we removed patients (two 
from IPCRESS and one from PANDA) with missing data on 
over 75% of baseline variables.
2.2 | Ethical considerations
All studies were granted NHS Research ethical approvals and 
all participants gave informed consent, see Table S2. No ad-
ditional ethical approval was required for this study: HRA 
reference 712/86/32/81.
2.3 | Data analysis plan
2.3.1 | Outcomes
Primary Outcome: Depressive symptom scale score at 
3– 4  months post- baseline. Five studies used the BDI- II at 
the primary end point, with one using the PHQ- 9 only at 
that point (COBALT, although both the PHQ- 9 and BDI- II 
were used at baseline in that study, Table 2). These outcomes 
were made comparable between studies in two ways: 1) the 
standardized mean (“z- score”) of the primary depressive 
symptom measure score used at 3– 4  months post- baseline 
in each study. The score at 3– 4 months was divided by the 
standard deviation for that measure across all studies, cal-
culated at 3– 4  months. 2) The logarithm (“log outcome”) 
of 3– 4 months depression scale scores combined across all 
studies irrespective of the measure used (this was controlled 
for by including the random allocation in each study in all 
models, as detailed below).
Secondary Outcomes: 1) remission on the BDI- II or 
PHQ- 9 at 3– 4 months (for definitions see Table 1); and 2) 
z- score of the depressive symptom scale at 6– 8 months post- 
baseline (available in four studies).
2.3.2 | Predictors under consideration
Potential baseline predictors of outcome were the total so-
cial support score as a continuous variable (sum of all eight 
items each scored 1– 3) and in three categories defined by the 
original scale authors: a severe lack of social support (scoring 
below 19); a moderate lack of social support (scores between 
19 and 23); and no lack of social support (scoring 24), these 
were modeled using dummy variables for severe and mod-
erate lack of social support. Individual items of the Social 
Support Scale were also investigated as continuous variables. 
To make estimates across the social support variables com-
parable, each continuous variable was z- score standardized.
2.3.3 | Confounding
Following our protocol3 the treatment randomization in each 
study was adjusted for in all models, we then added factors a 
priori considered to be important confounders (age, gender, 
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marital status, and employment status) determined with the use 
of directed acyclic graphs 26 and consideration of associations 
between the potential confounders and outcomes from previ-
ous studies using similar data.4 We then adjusted for the BDI- II 
score at baseline, and then additionally adjusted for the duration 
of anxiety, the duration of depression, comorbid panic disorder, 
and a history of treatment with antidepressant medications.
2.3.4 | Assessing properties of the social 
support scale
Before conducting the primary analyses, an exploratory prin-
cipal component analysis was conducted to identify any dis-
tinct underlying components within the Social Support Scale 
that may inform later analyses. As the eight- item version of 
the scale had not previously been validated (although a scale 
containing the first seven items has been25), analyses were 
conducted to determine the internal consistency, split- half 
reliability, discriminant validity, and latent structure of the 
Social Support Scale, using an Item Response Theory (IRT) 
based analysis, see Supplementary Materials (including 
Table S3) for details, and results from these analyses.
2.3.5 | Primary analyses
For each social support variable and each outcome, we built 
four models sequentially adding confounding variables in the 
order described above.
Two- stage DerSimonian and Laird random effects meta- 
analyses were conducted using “admetan” in Stata.27 Analyses 
could have been performed using one- stage approaches as have 
been conducted in other IPDs.2,28 The approaches would have 
given very similar results here although as the two- stage ap-
proach is considered less prone to bias in determining between- 
study effects it considered the most suitable.27
All outcomes were modeled with linear regression, ex-
cept for remission for which logistic regression were fitted. 
For the log outcome, exponentiating the coefficient for the 
prognostic indicator (exposure) variable gives an estimate 
of the percentage difference in symptoms per unit- change in 
the exposure variable relative to the mean (ie, this is not a 
measure of pre- post treatment change in symptoms). It can 
be expected that the two methods of capturing the primary 
outcome will give similar results in terms of the direction 
of association between the social support variables and out-
come, but as percentage differences might be more easily un-
derstood by patients and clinicians, results when using the 
log outcome might have greater clinical utility.
The degree of heterogeneity was assessed using predic-
tion intervals and its impact assessed using the I2 statistic.29
2.4 | Sensitivity analyses
Sensitivity analyses were conducted where heterogene-
ity was problematic (eg, with I2 above 75%), removing the 
study contributing most to the heterogeneity, and removing 
any studies that were rated as having moderate or high risks 
of bias, or that offered a low quality of evidence. Further 
sensitivity analyses were conducted using the multidimen-
sional IRT conversion of BDI- II scores and PHQ- 9 scores 
at 3– 4  months post- baseline to the PROMIS T- score, and 
the same analyses using the BDI- II score at 3– 4 months in 
the five studies that had these data. In addition, a quadratic 
T A B L E  2  Description of included studies
Study N Inclusion criteria
Age in years Gender
T0 depressive symptom 
severity
T0 CISR- Total 
Score
T0 social support 
total score
Remission Interventions
Depressive symptom outcome 
measure at 3– 4 monthsMean (SD) % Female Mean (SD) Mean (SD) Mean (SD)
COBALT 47 469 Adults 18– 75 with treatment resistant depression, 
scoring ≥14 BDI- II
49.6 (11.7) 72% BDI- II = 31.8 (10.7) 30.1 (8.9) 20.0 (3.8) 34% CBT+TAU vs TAU PHQ−9
GENPOD 48 601 Adults 18– 74 with depressive episode 38.8 (12.4) 68% BDI- II = 33.7 (9.7) 30.8 (8.0) 20.0 (3.8) 41% Citalopram vs Reboxetine BDI- II & HADS
IPCRESS 49 295 Adults scoring ≥14 BDI- II and GP confirmed diagnosis 
of depression
34.9 (11.6) 68% BDI- II = 33.2 (8.8) 29.6 (8.7) 20.0 (3.8) 34% iCBT+TAU vs TAU +waiting list for iCBT BDI- II
MIR 50 480 Adults ≥18 taking SSRIs or SNRIs at adequate dose 
for≥6 weeks, and scored ≥14 on BDI- II
50.7 (13.2) 69% BDI- II = 31.1 (9.9) 27.7 (8.3) 20.5 (4.1) 30% Mirtazapine vs Placebo BDI- II & PHQ−9
PANDA 51 652 Adults presenting with low mood or depression to GP in 
last 2 years, free of ADM for 8 weeks up to baseline
39.7 (15.0) 59% BDI- II = 23.9 (10.3) 21.3 (10.1) 20.6 (3.8) 69% Sertraline vs Placebo BDI- II & PHQ−9
TREAD 52 361 Adults 18– 69 who met diagnostic criteria for MDD and 
scored ≥14 on BDI- II
39.8 (12.6) 66% BDI- II = 32.1 (9.2) 28.1 (7.8) 20.1 (3.8) 35% Physical Activity +TAU vs TAU BDI- II
Abbreviations: ADM, Antidepressant medication; BDI- II, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; iCBT (internet based therapist  
delivered cognitive behavioral therapy); MDD, Major Depressive Disorder; PHQ- 9, Patient Health Questionnaire— nine item version; T0, Baseline; TAU, treatment  
as usual.
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relationship between outcome at 3– 4  months and the total 
score on the Social Support Scale was assessed.
2.5 | Data handling and data management
Details of the pre- processing stages and handling of miss-
ing data including specifications for multiple imputation per-
formed in each study can be found in the study protocol.4
2.6 | Risk of bias and evidence quality
Two reviewers (JB & RS) independently rated the risk of 
bias in each study using the Quality in Prognosis Studies 
(QUIPS)30 and rated the quality of evidence for each prog-
nostic indicator using the Grading Recommendations, 
Assessment, Development and Evaluations (GRADE) 
framework.31
3 |  RESULTS
3.1 | Characteristics of the included studies
In total, six RCTs met the inclusion criteria. IPD from all 
2858 participants formed the present dataset, see Figure 1.
3.2 | Quality assessments and risk of bias
Risk of bias was low and quality was high in all studies, so 
no sensitivity analyses were required in relation to these, see 
Table S4. There was near perfect agreement between the re-
viewers, with interrater reliability (Cohen's Kappa) k = 0.96 
for QUIPS and k = 1.00 for GRADE. Disagreements were 
resolved in consensus meetings with two further reviewers 
(SP and GL).
3.3 | Descriptive statistics
Approximately 67% of the participants were female, age 
at baseline ranged between 18 and 84  years old (mean 
(SD)  =  42.5(14.1) years), 94% were from white ethnic 
backgrounds, approximately two- thirds had a history of 
antidepressant treatment, and one third had been depressed 
for at least one year at the point of their baseline assess-
ments. On average, participants scored in the severe range 
on the BDI- II and most had a moderate lack of social sup-
port, see Table 3.
The correlation between the total social support score and 
baseline depressive symptom severity (r = −.29) and the cor-
relation between the total social support score and the z- score 
of depressive symptoms at 3– 4 months (r = −.18) were not 
strong by conventional standards.32
3.4 | The association between social 
support and prognosis
The total score on the Social Support Scale was associated 
with the severity of depressive symptoms at 3– 4 months, 
independent of treatment type and additionally adjusted 
for age, gender, marital status, and employment status, 
see Table 4. Controlling for depressive symptom severity 
T A B L E  2  Description of included studies
Study N Inclusion criteria
Age in years Gender
T0 depressive symptom 
severity
T0 CISR- Total 
Score
T0 social support 
total score
Remission Interventions
Depressive symptom outcome 
measure at 3– 4 monthsMean (SD) % Female Mean (SD) Mean (SD) Mean (SD)
COBALT 47 469 Adults 18– 75 with treatment resistant depression, 
scoring ≥14 BDI- II
49.6 (11.7) 72% BDI- II = 31.8 (10.7) 30.1 (8.9) 20.0 (3.8) 34% CBT+TAU vs TAU PHQ−9
GENPOD 48 601 Adults 18– 74 with depressive episode 38.8 (12.4) 68% BDI- II = 33.7 (9.7) 30.8 (8.0) 20.0 (3.8) 41% Citalopram vs Reboxetine BDI- II & HADS
IPCRESS 49 295 Adults scoring ≥14 BDI- II and GP confirmed diagnosis 
of depression
34.9 (11.6) 68% BDI- II = 33.2 (8.8) 29.6 (8.7) 20.0 (3.8) 34% iCBT+TAU vs TAU +waiting list for iCBT BDI- II
MIR 50 480 Adults ≥18 taking SSRIs or SNRIs at adequate dose 
for≥6 weeks, and scored ≥14 on BDI- II
50.7 (13.2) 69% BDI- II = 31.1 (9.9) 27.7 (8.3) 20.5 (4.1) 30% Mirtazapine vs Placebo BDI- II & PHQ−9
PANDA 51 652 Adults presenting with low mood or depression to GP in 
last 2 years, free of ADM for 8 weeks up to baseline
39.7 (15.0) 59% BDI- II = 23.9 (10.3) 21.3 (10.1) 20.6 (3.8) 69% Sertraline vs Placebo BDI- II & PHQ−9
TREAD 52 361 Adults 18– 69 who met diagnostic criteria for MDD and 
scored ≥14 on BDI- II
39.8 (12.6) 66% BDI- II = 32.1 (9.2) 28.1 (7.8) 20.1 (3.8) 35% Physical Activity +TAU vs TAU BDI- II
Abbreviations: ADM, Antidepressant medication; BDI- II, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; iCBT (internet based therapist  
delivered cognitive behavioral therapy); MDD, Major Depressive Disorder; PHQ- 9, Patient Health Questionnaire— nine item version; T0, Baseline; TAU, treatment  
as usual.
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the magnitude of effect was reduced, and it was very mar-
ginally affected further by additionally adjusting for the 
depressive “disorder characteristic” variables. There was 
evidence for differences in prognosis by category of social 
support based on the total score. After adjusting for all 
variables above, there was evidence that those with a se-
vere lack of social support had higher depressive symptom 
scale scores at 3– 4 months than those with no lack of social 
support (difference in z- score at 3– 4 months: 0.13(95%CI: 
0.03 to 0.23)), the difference in prognosis was particularly 
stark when comparing those with no lack of social sup-
port to those with the lowest scores on the scale (percent-
age difference in depressive symptoms at 3– 4  months: 
−22.83%(95%CI: −35.69 to −7.39)), but there was no 
evidence for a difference between those with a moderate 
lack of social support compared to no lack of social support 
(0.04(95%CI: −0.05 to 0.12): see Table 4). The z- score and 
log outcomes gave very similar results in terms of the di-
rection and magnitudes of associations between the social 
support variables and prognosis.
The findings with the secondary outcomes at 3– 4 months 
were similar to those with the primary outcome: For every 
z- score increase in the total score on the Social Support Scale 
at baseline, there was an increase in the odds of reaching 
remission (Table  5). However, the association was some-
what weaker with the outcome at 6– 8 months (Table 5). In 
sensitivity analyses using the PROMIS T- score, there was 
a similar pattern of results to the primary outcome. There 
was also a similar pattern of results when using the BDI- II 
score at 3– 4 months as an outcome in the five studies that 
had these data. There was little heterogeneity in the effects 
so no further sensitivity analyses were deemed necessary. In 
addition, we found no evidence for a quadratic relationship 
between the total social support scale score and prognosis at 
3– 4 months (p =.999).
3.5 | The associations between individual 
items of social support and prognosis
There was evidence that all eight of the Social Support Scale 
items were associated with prognosis independent of treat-
ment age, gender, marital status, and employment status, see 
Table 4. However, the magnitudes of association were dif-
ferent between the individual scale items, and there was only 
sufficient evidence that three items were associated with the 
outcome after additionally adjusting for depressive symptom 
severity and depressive “disorder characteristics”. These 
three items were as follows: 1) whether or not one feels ac-
cepted for who one is, by family and friends; 2) whether 
or not one feels cared about by family and friends; and 3) 
whether or not one feels supported or encouraged by family 
and friends, see Tables 4- 5. There was no clear evidence of 
an association between any of the individual items and prog-
nosis at 6– 8  months post- baseline, see Table  5. Results of 
sensitivity analyses were very similar to those of the primary 
analyses (Table 5).
T A B L E  3  Baseline characteristics of study sample
Self- reported baseline 
characteristics Factor
N (%), or 
Mean (SD)
Social support Total score 20.25 (3.85)
Accepted 2.56 (0.60)




Made to feel happy 2.42 (0.64)
Made to feel important 2.46 (0.66)
Made to feel loved 2.60 (0.58)
Can rely on others 2.59 (0.61)
Can talk to others 2.34 (0.71)
Age 42.52 (14.12)
Gender Female 1900 (67%)
Male 956 (33%)
Other 0
Ethnicity White 2698 (94%)
Non- White 159 (6%)





Marital status Married/cohabiting 1379 (48%)
Single 911 (32%)
No longer married 568 (20%)
Number of recent life 
events
1.35 (1.24)
Past Antidepressant use No 908 (32%)
Yes 1950 (68%)








Baseline BDI- II score 30.44 (1.53)
3– 4 month BDI- II 
score
16.07 (11.99)
6– 8 month BDI- II 
score
18.64 (13.44)
Remission 3– 4 months No 1363 (58%)
Yes 1005 (42%)
Attrition at 3– 4 months No 2382 (83%)
Yes 476 (17%)
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4 |  DISCUSSION
Social support was associated with prognosis independent 
of treatment type and after adjusting for socio- demographic 
factors. Prognosis was poorer for those with a severe lack of 
social support pre- treatment relative to those with no lack of 
support. The effects were considerably reduced after adjust-
ing for clinical markers of depressive severity, to the point 
that differences in prognosis may not be of clinically impor-
tant magnitudes.33 Three of the individual items of the Social 
F I G U R E  1  Flow diagram of study selection
Records excluded (n=46)
28= Not RCTs (11 diagnostic/screening 
instrument studies; 7 cohort studies, 3 
reviews; 3 non-randomised studies; 2 
study protocols; 1 economic evaluation 
study)
5= Not studies of depression 
2= Studies of depression and anxiety
2= Small feasibility trials 
5= Not recruited from GP 
4= Studies of children
Records identified from electronic 
database searching (n= 150)
Cochrane CENTRAL 49; Embase 33; IPA 






















Additional records identified 
through other sources (n= 1)
1 from correspondence with experts 
0 From hand searching of references





6= Not relevant to research question
6= Protocols not trials
4= Pilot studies superseded by another 
full trial also returned in search
15= Secondary publications/duplicates
Studies assessed for 
eligibility
(n= 59)
Study teams contacted for 
IPD (n = 13)
Included in Dep-GP IPD dataset
(n = 6)
Records excluded (n=7)
7= Did not use Social Support scale
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Support Scale had larger magnitudes of association and were 
more consistently associated with prognosis across the out-
comes than the other five items. These items were “feeling 
accepted,” “feeling cared about,” and “feeling supported 
or encouraged” by friends and family. There was little het-
erogeneity in the effects, supporting the robustness of these 
findings.
4.1 | Findings in context
Recent systematic reviews have suggested that patients con-
sider social support to be among the most important factors 
influencing their mood and outcomes from treatment,34 al-
though there has been very limited evidence of an association 
between social support and prognosis for depressed patients. 
Despite this, there has been a growing emphasis on social 
support and related constructs such as loneliness as poten-
tial targets for intervention as they are thought to both af-
fect the likelihood of seeking treatment and of engaging in 
and completing treatment, and hence effect treatment out-
comes.11,13,35 The present study found an association be-
tween social support and prognosis independent of a range of 
treatments offered to adults seeking treatment for depression 
in primary care. Adjusting for depressive severity had a large 
impact on the magnitude of the associations between social 
support variables and outcomes. In absolute terms, in the five 
studies that used the BDI- II at 3– 4 months, prior to adjusting 
for the severity factors the BDI- II scores were approximately 
5 points higher at 3– 4 months for those with a severe lack of 
social support compared to no lack of social support. After 
adjusting for the severity and other confounding factors, 
the difference in scores was only approximately 1.5 points. 
This is in keeping with our recent study that showed that de-
pressive symptom severity is the largest single indicator of 
prognosis for adults with depression in primary care.4 Many 
prior studies have suggested a multidimensional nature to so-
cial support.8 However, in this study, all items of the Social 
Support Scale were found to be highly correlated with a sin-
gle principal component, and the IRT analysis suggested a 
single latent factor with each item adequately able to be used 
to discriminate those with different levels of social support.
4.2 | Strengths and limitations
To our knowledge, this is the first study to use a large individ-
ual patient dataset formed from a number of RCTs to consider 
T A B L E  5  Associations of Social Support with secondary outcomes and sensitivity outcomes, adjusted for treatment, age, gender, marital 
status, employment status, depressive symptom severity, depressive “disorder characteristics,” and covariates
Social support 
indicator
Secondary outcomes Sensitivity analysis
Remission at 
3– 4 months
Depression z- score at 
6– 8 months
PROMIS T- Score at 3– 4 
Months









Severe lack vs No 
lack
0.68 (0.52 to 0.88) 0 0.04 (−0.10 to 0.19) 0 1.84 (0.62 to 3.05) 5 1.52 (0.08 to 2.95) 11
Moderate lack vs No 
lack
0.89 (0.71 to 1.11) 0 0.02 (−0.10 to 0.15) 0 0.88 (−0.15 to 1.90) 4 0.16 (−0.94 to 1.25) 0
Per one SD increase
Total score 1.15 (1.04 to 1.27) 0 −0.04 (−0.09 to 0.02) 0 −0.60 (−1.05 to −0.15) 0 −0.54 (−1.06 to −0.02) 0
Accepted 1.11 (1.01 to 1.23) 0 −0.04 (−0.10 to 0.01) 0 −0.68 (−1.11 to −0.24) 0 −0.70 (−1.22 to −0.18) 0
Cared about 1.14 (1.03 to 1.26) 0 −0.03 (−0.08 to 0.03) 0 −0.56 (−1.00 to −0.13) 0 −0.47 (−0.98 to 0.04) 0
Made to feel 
happy
1.09 (0.99 to 1.20) 0 −0.02 (−0.08 to 0.03) 0 −0.39 (−0.81 to 0.03) 0 −0.21 (−0.70 to 0.28) 0
Made to feel 
important
1.09 (0.99 to 1.20) 0 0.00 (−0.05 to 0.06) 0 −0.12 (−0.56 to 0.32) 0 −0.07 (−0.57 to 0.43) 0
Made to feel loved 1.13 (1.03 to 1.24) 0 −0.05 (−0.11 to 0.02) 30 −0.36 (−0.79 to 0.07) 0 −0.58 (−1.09 to −0.08) 0
Can rely on others 1.12 (1.01 to 1.23) 0 −0.03 (−0.09 to 0.02) 0 −0.43 (−0.86 to −0.01) 0 −0.53 (−1.11 to 0.04) 24
Supported or 
encouraged
1.14 (1.04 to 1.25) 0 −0.04 (−0.09 to 0.02) 0 −0.64 (−1.06 to −0.21) 0 −0.45 (−094 to 0.05) 0
Can talk to others 1.08 (0.98 to 1.19) 0 −0.02 (−0.07 to 0.03) 0 −0.44 (−0.86 to −0.02) 18 −0.34 (−0.83 to 0.15) 0
Note: All models adjusted for random allocation in each study, depressive symptom severity, average anxiety duration, depression duration, panic disorder, and a 
history of antidepressant treatment, gender, age, marital status, and employment status.
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the associations between social support and prognosis inde-
pendent of a number of types of treatment. We selected stud-
ies that only recruited participants in primary care so findings 
could be generalizable to large proportions of adults seek-
ing treatment for depression. Data were extracted, cleaned, 
and checked by multiple reviewers, adding robustness to the 
methods.36 Studies had to use the same measures to deter-
mine diagnosis, assess baseline symptoms, social support and 
confounders so we can have confidence in the ability to use 
the same measures in clinical practice to inform prognosis. 
Although this reduced bias in harmonizing data it limited the 
number of studies meeting inclusion criteria here. Further, 
although adjustments were made for a number of potential 
confounders, including clinical, demographic, and socio- 
economic variables, we cannot rule out residual confounding. 
Further, it is possible that adjusting for baseline depression 
severity may have led to underestimating or overestimating 
the effects of social support on prognosis, as baseline sever-
ity might have been affected by levels of social support at 
baseline. This study was not able to address questions of the 
causal pathway between social support and prognosis, but ad-
justing for factors routinely assessed in clinic is important to 
the discovery of clinically informative findings, regardless of 
the causal pathways. Hence, we adjusted for baseline severity 
as this should be routinely assessed in clinic.
In addition, the data used here were self- reported and 
this may have led to additional measurement error; we might 
expect those with greater baseline depression severity to be 
least likely to rate their own social support to be high, in-
creasing bias. However, adjustments were made for all de-
pression severity factors associated with the outcomes and 
social support variables, not just the severity of depressive 
symptoms, minimizing the potential for such bias here, and 
potentially increasing utility.37 Further, using a standardized 
outcome is a method that has been criticized previously but 
the results using the z- score outcome were similar to those 
with the log outcome and the secondary and sensitivity out-
comes, suggesting the use of the standardized outcome met-
ric did not unduly affect the results.
Finally, overall the scores on the Social Support Scale 
were high; just under half of the sample scored 21 or over and 
approximately 29% of the sample had the maximum score of 
24 on the Social Support Scale. However, scores under the 
maximum on the measure used here are indicative of a lack 
of social support so a highly skewed pattern of responses to 
the questions of the scale were expected.25,38
4.3 | Implications and conclusions
It is difficult to assess the clinical importance of prognostic 
factors. One approach is to compare the differences we ob-
served with estimates for the minimal clinically important 
difference. Previous work has suggested this is about 17.5% 
for the BDI- II.33 By this criterion, only the difference in prog-
nosis for those with the lowest scores on the Social Support 
Scale compared to those with no lack of social support (the 
maximum score) would be considered clinically important. 
So, assessing levels of perceived social support prior to com-
mencing treatment could be informative for the management 
of depression. However, only a small proportion of patients 
are likely to have either the lowest score or maximum score 
on the Social Support Scale (this was applicable to only 30% 
of our study sample). Associations were of a lower magnitude 
after adjusting for clinical prognostic factors and so meas-
uring those in clinic, will be more informative than assess-
ing for social support. Future studies might investigate the 
causal pathways between social support and prognosis, and 
whether it is beneficial to directly address a lack of social 
support by augmenting treatment with interventions targeted 
at increasing social contacts and improving the quality of re-
lationships with family and friends. There are a number of 
interventions that are thought to have the potential to affect 
the number or quality of social relationships which might be 
particularly worth investigating; these include Interpersonal 
Psychotherapy,39 Dynamic Interpersonal Therapy,40 and work 
with Community Navigators.41 Further, future studies might 
investigate the impact of offering more regular reviews and 
more intensive treatments to those reporting a severe lack of 
social support, in order to mitigate the risk of poor prognosis.
Given the psychometric properties of the Social Support 
Scale, it is reasonable to suggest that any of the eight items 
could be used to capture aspects of social support although if 
using only one then feeling “accepted by family and friends,” 
feeling “supported or encouraged by family or friends,” and 
feeling “cared about by family or friends,” might be most in-
formative if the whole scale is not able to be used.
Other measures related to but separate from social sup-
port, particularly those assessing loneliness and social iso-
lation, could be important additions to assessments in future 
studies and could prove informative as potential targets for in-
terventions whether in or outside of the therapy room.16,35,42 
Future research should consider the unique contribution of 
each of these issues to determining prognosis for adults with 
depression and any interactions between them.
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